Treatment of infections caused by metallo-β-lactamase-producing Pseudomonas aeruginosa in the Calgary Health Region

Clinical Microbiology and Infection

Volumn 13, Issue 2, 2007, Pages 199-202

  Parkins, M D ^a   Pitout, J D D ^b,c   Church, D L ^a,b,c   Conly, J M ^a,b,c   Laupland, Kevin B ^a,b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b CALGARY HEALTH REGION   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Aztreonam; Colistin; Infections; Metallo lactamase; Pseudomonas aeruginosa; Therapy

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; STEROID; TAZOBACTAM; TOBRAMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL PERITONITIS; CANADA; CATHETER INFECTION; CONTROLLED STUDY; DEATH; DRUG USE; ENZYME SYNTHESIS; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SOFT TISSUE INFECTION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; URINARY TRACT INFECTION;

PSEUDOMONAS AERUGINOSA;

EID: 33846287153     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01591.x     Document Type: Article

References (20)

1. Jones RN, Biedenbach DJ, Sader HS, Fritsche TR, Toleman MA, Walsh TR. Emerging epidemic of metallo-beta-lactamase-mediated resistances. Diagn Microbiol Infect Dis 2005; 51: 77-84.
2. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: The quiet before the storm? Clin Microb Rev 2005; 18: 306-325.
3. Poirel L, Naas T, Nicolas D et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 2000; 44: 891-897.
4. Riccio ML, Pallecchi L, Docquier JD et al. Clonal relatedness and conserved integron structures in epidemiologically unrelated Pseudomonas aeruginosa strains producing the VIM-1 metallo-β-lactamase from different Italian hospitals. Antimicrob Agents Chemother 2005; 49: 104-110.
5. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005; 11: 17-32.
6. Hirakata Y, Yamaguchi T, Nakano M et al. Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa. Clin Infect Dis 2003; 37: 26-32.
7. Laupland KB, Parkins MD, Church DL et al. Population-based epidemiology of carbapenem resistant Pseudomonas aeruginosa infections in the Calgary Health Region: Importance of metallo-β-lactamase producing isolates. J Infect Dis 2005; 192: 1606-1612.
8. Pitout JD, Gregson DB, Poirel L, McClure JA, Le P, Church DL. Detection of Pseudomonas aeruginosa producing metallo-β-lactamases in a large centralized laboratory. J Clin Microbiol 2005; 43: 3129-3135.
9. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 14th informational supplement. M100-S14. Wayne, PA: NCCLS, 2004.
10. Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. Molecular characterization of a β-lactamase gene, bla GIM-1, encoding a new subclass of metallo-β-lactamase. Antimicrob Agents Chemother 2004; 48: 4654-4661.
11. Toleman MA, Simm AM, Murphy TA et al. Molecular characterization of SPM-1, a novel metallo-β-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother 2002; 50: 673-679.
12. Bellais S, Mimoz O, Leotard S, Jacolot A, Petitjean O, Nordmann P. Efficacy of beta-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-beta-lactamase-producing strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 2032-2034.
13. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003:37: e154-e160.
14. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: R78-R83.
15. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-1011.
16. Mubareka S, Rubinstein E. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005; 9: 29-30.
17. Vidal F, Mensa J, Almela M et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996; 156: 2121-2126.
18. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87: 540-546.
19. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47: 2756-2764.
20. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: Importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49: 1306-1311.